Geron’s Rytelo Approved, Paving The Way For First Commercial Launch
Rytelo is a first-in-class telomerase inhibitor approved for the treatment of lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
Rytelo is a first-in-class telomerase inhibitor approved for the treatment of lower-risk myelodysplastic syndromes with transfusion-dependent anemia.